Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 10/20 | 0.46 |
| ▸ | CA2 | P00918 | 10/20 | 0.46 |
| ▸ | CA12 | O43570 | 7/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15468365 | 0.99 | TDP1 (0.49) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL13855533 | 0.88 | TDP1 (0.44) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL29774455 | 0.88 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL15468364 | 0.87 | TDP1 (0.43) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL21065333 | 0.84 | TDP1 (0.62) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL18484173 | 0.82 | TSHR (0.53) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL22602535 | 0.82 | TDP1 (0.53) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL463171 | 0.82 | TDP1 (0.53) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL22602576 | 0.81 | TDP1 (0.51) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL20755615 | 0.81 | TDP1 (0.51) | TDP1MEN1GAAKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136443-A1 | Drug Carrier | OXGENIX CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136443-A1 | Drug Carrier | ABCB11, SLC47A1, SLC47A2 | TDP1 3932/4885MEN1 2676/4885GAA 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.